MTST (MetaStat) Operating Margin %: 0.00% (As of Feb. 2018)


What is MetaStat Operating Margin %?

MetaStat MTST Operating Margin % is 0.00% as of Feb. 2018.

Operating Margin % is calculated as Operating Income divided by its Revenue. MetaStat's Operating Income for the three months ended in Feb. 2018 was $-0.88 Mil. MetaStat's Revenue for the three months ended in Feb. 2018 was $0.00 Mil. Therefore, MetaStat's Operating Margin % for the quarter that ended in Feb. 2018 was 0.00%.

The historical rank and industry rank for MetaStat's Operating Margin % or its related term are showing as below:


MTST's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.83
* Ranked among companies with meaningful Operating Margin % only.

MetaStat's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

MetaStat's Operating Income for the three months ended in Feb. 2018 was $-0.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2018 was $-3.55 Mil.


MetaStat  (OTCPK:MTST) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


MetaStat Operating Margin % Related Terms


MetaStat Operating Margin % Historical Data

* Premium members only.

The historical data trend for MetaStat's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Operating Margin % Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -15,439.13

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3,204.35 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: Operating Margin % Comparison

For the Biotechnology subindustry, MetaStat's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Operating Margin % distribution charts can be found below:

* The bar in red indicates where MetaStat's Operating Margin % falls into.



MetaStat Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

MetaStat's Operating Margin % for the fiscal year that ended in Feb. 2018 is calculated as

Operating Margin %=Operating Income (A: Feb. 2018 ) / Revenue (A: Feb. 2018 )
=-3.551 / 0.023
=-15,439.13 %

MetaStat's Operating Margin % for the quarter that ended in Feb. 2018 is calculated as

Operating Margin %=Operating Income (Q: Feb. 2018 ) / Revenue (Q: Feb. 2018 )
=-0.878 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
MetaStat (MTST) has a Operating Margin % of 0.00% as of Feb. 2018. Operating margin is the ratio of total operating income to net sales. View historical data on MetaStat and its competitors.
Is MetaStat's Operating Margin % too high?
MetaStat's current Operating Margin % is 0.00%.
How does MetaStat's Operating Margin % compare to OBMP and NSPX?
MetaStat's Operating Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on MetaStat and its competitors. MetaStat's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For MetaStat (MTST), the current Operating Margin % is 0.00% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.